Rating:
Outperform
DRTX
181.39 %
Durata Therapeutics Inc. (DRTX) rated Outperform by Credit Suisse
Credit Suisse rated Outperform Durata Therapeutics Inc. (NASDAQ: DRTX) on 03/15/2013. Previously Credit Suisse rated Outperform Durata Therapeutics Inc. (NASDAQ: DRTX) on
08/14/2012., when the stock price was $8.44. Since then, Durata Therapeutics Inc. has gained 181.40% as of 11/14/2014's recent price of $23.75. If you would have followed the previous Credit Suisse's recommendation on DRTX, you would have gained 181.39% of your investment in 822 days.
Excellence in equity and fixed income research is a hallmark of
Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally,
Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.